Kimberly H. Allison

31.6k total citations · 9 hit papers
114 papers, 13.7k citations indexed

About

Kimberly H. Allison is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Kimberly H. Allison has authored 114 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 55 papers in Cancer Research and 39 papers in Pathology and Forensic Medicine. Recurrent topics in Kimberly H. Allison's work include Breast Cancer Treatment Studies (47 papers), Breast Lesions and Carcinomas (33 papers) and HER2/EGFR in Cancer Research (27 papers). Kimberly H. Allison is often cited by papers focused on Breast Cancer Treatment Studies (47 papers), Breast Lesions and Carcinomas (33 papers) and HER2/EGFR in Cancer Research (27 papers). Kimberly H. Allison collaborates with scholars based in United States, Canada and United Kingdom. Kimberly H. Allison's co-authors include Antonio C. Wolff, Lisa M. McShane, Mitch Dowsett, Patrick L. Fitzgibbons, Giuseppe Viale, Patricia A. Spears, M. Elizabeth Hammond, Pamela B. Mangu, Michael F. Press and Wedad Hanna and has published in prestigious journals such as JAMA, Nature Materials and Journal of Clinical Oncology.

In The Last Decade

Kimberly H. Allison

111 papers receiving 13.5k citations

Hit Papers

Recommendations for Human... 2013 2026 2017 2021 2013 2018 2013 2018 2020 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 3.1k citations Antonio C. Wolff, M. Elizabeth Hammond et al. Journal of Clinical Oncology profile →
  2. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
    2018 1.5k citations Antonio C. Wolff, M. Elizabeth Hammond et al. Journal of Clinical Oncology profile →
  3. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 1.3k citations Antonio C. Wolff, M. Elizabeth Hammond et al. Archives of Pathology & Laboratory Medicine profile →
  4. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
    2018 1.0k citations Antonio C. Wolff, M. Elizabeth Hammond et al. Archives of Pathology & Laboratory Medicine profile →
  5. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    2020 851 citations Kimberly H. Allison, M. Elizabeth H. Hammond et al. Journal of Clinical Oncology profile →
  6. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium
    2014 671 citations Kimberly H. Allison et al. profile →
  7. The 2019 World Health Organization classification of tumours of the breast
    2020 547 citations Puay Hoon Tan, Ian O. Ellis et al. Histopathology profile →
  8. Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens
    2015 440 citations Kimberly H. Allison, Stuart J. Schnitt et al. profile →
  9. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
    2023 251 citations Antonio C. Wolff, Mark R. Somerfield et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kimberly H. Allison United States 44 7.6k 5.7k 3.5k 2.6k 2.6k 114 13.7k
Patrick L. Fitzgibbons United States 35 8.2k 1.1× 6.2k 1.1× 3.0k 0.9× 2.7k 1.0× 2.7k 1.1× 89 13.8k
Wedad Hanna Canada 45 10.6k 1.4× 7.6k 1.3× 3.5k 1.0× 4.6k 1.8× 2.7k 1.1× 156 17.0k
Edi Brogi United States 55 5.6k 0.7× 5.4k 0.9× 1.9k 0.5× 6.0k 2.3× 2.7k 1.0× 237 15.8k
Jelle Wesseling Netherlands 55 4.3k 0.6× 5.0k 0.9× 2.6k 0.7× 3.3k 1.3× 2.2k 0.8× 281 10.7k
Michael Bilous Australia 27 6.3k 0.8× 4.0k 0.7× 3.0k 0.8× 2.1k 0.8× 1.6k 0.6× 70 9.4k
David G. Hicks United States 49 6.2k 0.8× 3.9k 0.7× 2.6k 0.7× 4.4k 1.7× 1.3k 0.5× 185 12.3k
Suzette Delaloge France 56 8.4k 1.1× 5.0k 0.9× 1.6k 0.4× 3.4k 1.3× 1.4k 0.6× 399 13.9k
Savitri Krishnamurthy United States 59 5.0k 0.7× 6.1k 1.1× 1.1k 0.3× 2.4k 0.9× 3.8k 1.5× 277 11.9k
Michael Untch Germany 65 12.6k 1.7× 10.1k 1.8× 3.9k 1.1× 3.7k 1.4× 3.5k 1.4× 542 19.7k
Sunil Badve United States 59 6.4k 0.8× 4.6k 0.8× 897 0.3× 5.5k 2.1× 1.5k 0.6× 309 14.3k

Countries citing papers authored by Kimberly H. Allison

Since Specialization
Citations

This map shows the geographic impact of Kimberly H. Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly H. Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly H. Allison more than expected).

Fields of papers citing papers by Kimberly H. Allison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly H. Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly H. Allison. The network helps show where Kimberly H. Allison may publish in the future.

Co-authorship network of co-authors of Kimberly H. Allison

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly H. Allison. A scholar is included among the top collaborators of Kimberly H. Allison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly H. Allison. Kimberly H. Allison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winchester, David J., Stephen B. Edge, Kimberly H. Allison, et al.. (2025). Novel Postneoadjuvant Prognostic Breast Cancer Staging System. Journal of Clinical Oncology. 43(17). 1948–1960. 3 indexed citations
2.
Ellis, Ian O., Fleur Webster, Kimberly H. Allison, et al.. (2024). Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 85(3). 418–436. 3 indexed citations
3.
4.
Wolff, Antonio C., Mark R. Somerfield, Mitch Dowsett, et al.. (2023). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update. Journal of Clinical Oncology. 41(22). 3867–3872. 251 indexed citations breakdown →
5.
Thennavan, Aatish, Francisco Beça, Susana García‐Recio, et al.. (2021). Molecular analysis of TCGA breast cancer histologic types. Cell Genomics. 1(3). 100067–100067. 62 indexed citations
6.
Allison, Kimberly H., David G. Hicks, Karen K. Swenson, et al.. (2021). HER2 Testing: Insights From Pathologists’ Perspective on Technically Challenging HER2 FISH Cases. Applied immunohistochemistry & molecular morphology. 29(9). 635–642. 2 indexed citations
7.
Yang, Soo‐Ryum, Yosr Bouhlal, Francisco M. De La Vega, et al.. (2020). Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups. Modern Pathology. 33(8). 1546–1556. 12 indexed citations
8.
Beça, Francisco, Gregor Krings, Yunn‐Yi Chen, et al.. (2020). Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis. Modern Pathology. 33(8). 1518–1526. 19 indexed citations
9.
Allison, Kimberly H., M. Elizabeth H. Hammond, Mitch Dowsett, et al.. (2020). Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Archives of Pathology & Laboratory Medicine. 144(5). 545–563. 215 indexed citations
10.
Fitzpatrick, Megan B., Mara H. Rendi, Nancy B. Kiviat, et al.. (2019). Pathology of Senegalese breast cancers. Pan African Medical Journal. 34. 67–67. 11 indexed citations
11.
Bui, Marilyn M., Michael Riben, Kimberly H. Allison, et al.. (2018). Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists. Archives of Pathology & Laboratory Medicine. 143(10). 1180–1195. 59 indexed citations
12.
Wolff, Antonio C., M. Elizabeth Hammond, Kimberly H. Allison, et al.. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 36(20). 2105–2122. 1545 indexed citations breakdown →
13.
Allison, Kimberly H.. (2018). Ancillary Prognostic and Predictive Testing in Breast Cancer. Surgical pathology clinics. 11(1). 147–176. 4 indexed citations
14.
Lin, Chieh‐Yu, Daphne Y. Lichtensztajn, Scarlett Lin Gomez, et al.. (2017). Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California. American Journal of Clinical Pathology. 148(3). 199–207. 8 indexed citations
15.
Jalikis, Florencia G., Gregor Krings, Rodney A. Schmidt, et al.. (2016). ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study. Modern Pathology. 30(2). 227–235. 68 indexed citations
16.
Loiselle, Christopher, Peter R. Eby, Kristine E. Calhoun, et al.. (2013). Preoperative MRI Improves Prediction of Extensive Occult Axillary Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Lymph Node Biopsy. Academic Radiology. 21(1). 92–98. 15 indexed citations
17.
Upson, Kristen, Kimberly H. Allison, Susan D. Reed, et al.. (2012). Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. American Journal of Obstetrics and Gynecology. 207(1). 36.e1–36.e8. 43 indexed citations
18.
Kurland, Brenda F., Vijayakrishna K. Gadi, Jennifer M. Specht, et al.. (2012). Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Research. 2(1). 34–34. 28 indexed citations
19.
Allison, Kimberly H., Kristen Upson, Susan D. Reed, et al.. (2012). PAX2 Loss by Immunohistochemistry Occurs Early and Often in Endometrial Hyperplasia. International Journal of Gynecological Pathology. 31(2). 151–159. 24 indexed citations
20.
Zuna, Rosemary E., R Allen, William Moore, et al.. (2005). Dermatopathology. Laboratory Investigation. 85. 82–88. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick L. Fitzgibbons Breakdown of academic impact, for papers by Wedad Hanna Breakdown of academic impact, for papers by Edi Brogi Breakdown of academic impact, for papers by Jelle Wesseling Breakdown of academic impact, for papers by Michael Bilous Breakdown of academic impact, for papers by David G. Hicks Breakdown of academic impact, for papers by Suzette Delaloge Breakdown of academic impact, for papers by Savitri Krishnamurthy Breakdown of academic impact, for papers by Michael Untch Breakdown of academic impact, for papers by Sunil Badve
Rankless by CCL
2026